Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Book Chapter

Glycoproteomics Technologies in Glycobiotechnology


Alagesan,  Kathirvel
Max Planck Unit for the Science of Pathogens, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Alagesan, K., Hoffmann, M., Rapp, E., & Kolarich, D. (2020). Glycoproteomics Technologies in Glycobiotechnology. In Advances in Biochemical Engineering/Biotechnology. doi:10.1007/10_2020_144.

Cite as: https://hdl.handle.net/21.11116/0000-0008-F04C-4
Glycosylation is a key factor determining the pharmacological properties of biotherapeutics, including their stability, solubility, bioavailability, pharmacokinetics, and immunogenicity. As such, comprehensive information about glycosylation of biotherapeutics is critical to demonstrate similarity. Regulatory agencies also require extensive documentation of the comprehensive analyses of glycosylation-related critical quality attributes (CQAs) during the development, manufacturing, and release of biosimilars. Mass spectrometry has catalysed tremendous advancements in the characterisation of glycosylation CQAs of biotherapeutics. Here we provide a perspective overview on the MS-based technologies relevant for biotherapeutic product characterisation with an emphasis on the recent developments that allow determination of glycosylation features such as site of glycosylation, sialic acid linkage, glycan structure, and content.Graphical AbstractOpen image in new window